Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Measurement characteristics and clinical utility of the 29-item Multiple Sclerosis Impact Scale.
The many faces of impaired bladder emptying.
Paroxysmal dysarthria-ataxia in remitting-relapsing Bickerstaff's-like encephalitis.
Central auditory processing and word discrimination in patients with multiple sclerosis.
Palliative treatment of chronic neurologic disorders.
Epidemiology of Multiple Sclerosis in Iran: A Systematic Review.
The neurotrophic hepatocyte growth factor attenuates CD8+ cytotoxic T-lymphocyte activity.
Predictors of quality of life in patients with relapsing-remitting multiple sclerosis: A 2-year longitudinal study.
Cortical relapses in multiple sclerosis.
Predictors of chronic cerebrospinal venous insufficiency procedure use among older people with multiple sclerosis: a national case-control study.
Promoting Physical Activity through a Manual Wheelchair Propulsion Intervention in Persons with Multiple Sclerosis.
[Pulmonary lymphangioleiomyomatosis of unusual revelation during multiple sclerosis].
Including a subject-paced trial may make the PASAT more acceptable for MS patients.
Employment status in multiple sclerosis: impact of disease-specific and non-disease-specific factors.
Tamoxifen promotes differentiation of oligodendrocyte progenitors in vitro.
MRI to Discriminate Pediatric MS from ADEM.
Psychosocial difficulties from the perspective of persons with neuropsychiatric disorders.
An investigation of the relationship between latitude and multiple sclerosis severity in New Zealand.
microRNAs as neuroregulators, biomarkers and therapeutic agents in neurodegenerative diseases.
Isolation of highly enriched primary human microglia for functional studies.
Multiple sclerosis in the very young: a case report and review of the literature.
Clemastine Enhances Myelination in the Prefrontal Cortex and Rescues Behavioral Changes in Socially Isolated Mice.
Migraine Headaches And Pain With Neuropathic Characteristics: Comorbid Conditions In Patients With Multiple Sclerosis.
IL-27p28 inhibits central nervous system autoimmunity by concurrently antagonizing Th1 and Th17 responses.
Daclizumab, an IL-2 modulating antibody for treatment of multiple sclerosis.

Pages